{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aluminum+hydroxide",
    "query": {
      "intervention": "aluminum hydroxide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 128,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aluminum+hydroxide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T04:54:55.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06680479",
      "title": "Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "CH505 TF chTrimer",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum Hydroxide Suspension",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride for Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-01",
      "completion_date": "2028-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06680479"
    },
    {
      "nct_id": "NCT01666652",
      "title": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "4 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS03B1 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline",
          "type": "OTHER"
        },
        {
          "name": "1 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS01E1 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666652"
    },
    {
      "nct_id": "NCT06007183",
      "title": "Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chikungunya Virus Infection"
      ],
      "interventions": [
        {
          "name": "CHIKV VLP vaccine booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo booster",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 715,
      "start_date": "2023-08-30",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 24,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007183"
    },
    {
      "nct_id": "NCT00340431",
      "title": "Experimental Vaccine for Plasmodium Falciparum Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria",
        "Vaccines"
      ],
      "interventions": [
        {
          "name": "MSP1(42)-FVO & MSP1(42)-3D7",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2004-06-09",
      "completion_date": "2008-02-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00340431"
    },
    {
      "nct_id": "NCT00344539",
      "title": "AMA1-C1/Alhydrogel + CpG 7909 for Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria"
      ],
      "interventions": [
        {
          "name": "AMA1-C1/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CPG 7909 Oligodeoxynucleotide (VaxImmune®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 75,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00344539"
    },
    {
      "nct_id": "NCT05018585",
      "title": "A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Colecalciferol 2000 IU",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Diamyd Medical AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "28 Years",
        "sex": "ALL",
        "summary": "12 Years to 28 Years"
      },
      "enrollment_count": 321,
      "start_date": "2022-05-19",
      "completion_date": "2026-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 13,
      "location_summary": "Newport Beach, California • Palo Alto, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05018585"
    },
    {
      "nct_id": "NCT00296634",
      "title": "H5 Vaccine Alone or With Adjuvant in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 600,
      "start_date": "2006-03",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00296634"
    },
    {
      "nct_id": "NCT00529399",
      "title": "Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "GAD-Alum",
          "type": "DRUG"
        },
        {
          "name": "GAD-Alum and Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "3 Years to 45 Years"
      },
      "enrollment_count": 145,
      "start_date": "2009-02",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2020-05-07",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529399"
    },
    {
      "nct_id": "NCT02952833",
      "title": "ZIKA Vaccine in Naive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus Infection"
      ],
      "interventions": [
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Zika Virus Purified Inactivated Vaccine (ZPIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 91,
      "start_date": "2016-10-14",
      "completion_date": "2018-12-05",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952833"
    },
    {
      "nct_id": "NCT02475278",
      "title": "Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "NoV GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2015-02-26",
      "completion_date": "2015-09-09",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-09-10T04:54:55.745Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475278"
    }
  ]
}